Reply to 'Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia' by Dr Laurenti et al. [2]

Leukemia

Volumn 21, Issue 8, 2007, Pages 1821-

  Lundin, Jeanette ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB;

AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LEUKEMIA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; LETTER; LOW DRUG DOSE; PRIORITY JOURNAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 34447638713     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404704     Document Type: Letter

References (3)

1. Laurenti L, Tamani M, Efremov DG, Chiusolo P, De Padua L, Sica S et al. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia. Leukemia 2007, in press.
2. Karlsson C, Hansson H, Celsing F, Lundin J. Treatmens of severe refractory autoimmune hemolytic anemia (AIHA) in B-cell chronic lymphocytic leukemia (B-CLL) with alemtuzumab humanized CD52 monoclonal antibody. Leukemia 2007; 21: 511-514.
3. Hale G, Rebello P, Brettman L, Fegan C, Kennedy B, Kimby E et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004; 104: 948-955.